Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome

ÇUBUKÇU, ERDEM; Olmez, Omer; SARAYDAROĞLU, ÖZLEM; Akcali, Unsal; Kanat, Ozkan; Kurt, Ender; EVRENSEL, TÜRKKAN; Manavoglu, Osman

doi:10.1007/s12094-011-0741-7

Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome

ÇUBUKÇU E., Olmez O. F., SARAYDAROĞLU Ö., Akcali U., Kanat O., Kurt E., ...Daha Fazla

CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.13, sa.11, ss.826-830, 2011 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 13 Sayı: 11
Basım Tarihi: 2011
Doi Numarası: 10.1007/s12094-011-0741-7
Dergi Adı: CLINICAL & TRANSLATIONAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.826-830
Anahtar Kelimeler: Non-small-cell lung cancer, Excision repair cross-complementing 1, Immunohistochemistry, Prognosis, DNA-REPAIR, MESSENGER-RNA, CHEMOTHERAPY, BIOMARKERS, RESISTANCE, THERAPY, GENE
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour.